Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy

Clinical Journal of Gastroenterology

Volumn 2, Issue 3, 2009, Pages 214-217

  Okita, Riki ^a   Takahashi, Mamoru ^a   Narahara, Hiroyuki ^a   Sanada, Yuichi ^a   Okada, Morihito ^a   Kawakami, Yoshiiku ^a   Chayama, Kazuaki ^a   Okita, Kiwamu ^b  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b Shimonoseki Kosei Hospital   (Japan)

Author keywords

Chemotherapy; Entecavir; Hepatitis B virus; Solid malignancy; Steroid

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ENTECAVIR; EPIRUBICIN; HEPATITIS B SURFACE ANTIGEN; PACLITAXEL; STEROID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; DRUG CYTOTOXICITY; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SOLID TUMOR; VIRUS REACTIVATION;

EID: 77953404918     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-009-0063-2     Document Type: Article

References (19)

1. RM Galbraith AL Eddleston R Williams AJ Zuckerman 1975 Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy Lancet 2 528 530
2. JR Wands CM Chura FJ Roll WC Maddrey 1975 Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders Gastroenterology 68 105 112
3. RP Perrillo 2001 Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease Gastroenterology 120 1009 1022 (Pubitemid 32193199)
4. W Yeo WM Ho P Hui PKS Chan KC Lam JJ Lee PJ Johnson 2004 Use for lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients Breast Cancer Res Treat 88 209 215 (Pubitemid 40137299)
5. R Loomba A Rowley R Wesley TJ Liang JH Hoofnagle F Pucino G Csako 2008 Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy Ann Intern Med 148 519 528 (Pubitemid 351665421)
6. C Hsu CA Hsiung IJ Su WS Hwang MC Wang SF Lin TH Lin HH Hsiao JH Young MC Chang YM Liao CC Li HB Wu HF Tien TY Chao TW Liu AL Cheng PJ Chen 2008 A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial Hepatology 47 844 853
7. YH Li YF He WQ Jiang FH Wang XB Lin L Zhang ZJ Xia XF Sun HQ Huang TY Lin YJ He ZZ Guan 2006 Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma Cancer 106 1320 1325 (Pubitemid 43363909)
8. SF Innaimo M Seifer GS Bisacchi DN Standring R Zahler RJ Colonno 1997 Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus Antimicrob Agents Chemother 41 1444 1448 (Pubitemid 27289665)
9. TT Chang RG Gish R Man A Gadano J Sollano YC Chao AS Lok KH Han Z Goodman J Zhu A Cross D DeHertogh R Wilber R Zink R Colonno D Apelian 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 (Pubitemid 43357804)
10. CL Lai D Shouval AS Lok TT Chang H Cheinquer Z Goodman D DeHertogh R Wilber R Zink A Cross R Colonno L Fernandes 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 1011 1020 (Pubitemid 43357805)
11. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel Members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583. (Pubitemid 41511089)
12. R Liang GKK Lau YL Kwong 1999 Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem J Clin Oncol 17 394 398 (Pubitemid 29022418)
13. EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol 2003; 38: 533-540.
14. ASF Lok BJ McMahon 2004 Chronic hepatitis B: update of recommendations Hepatology 39 857 861 (Pubitemid 38337668)
15. R Ling D Mutimer M Ahmed EH Boxall E Elias GM Dusheiko TJ Harrison 1996 Selection of mutation in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 24 711 713 (Pubitemid 26296020)
16. CL Lai RN Chien NW Leung TT Chang R Guan DI Tai KY Ng PC Wu JC Dent J Barber SL Stephenson DF Gray 1998 A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 61 68 (Pubitemid 28304879)
17. JP Villeneuve LD Condreay B Willems G Pomier Layrargues D Fenyves M Bilodeau R Leduc K Peltekian F Wong M Margulies EJ Heathcote 2000 Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B Hepatology 31 207 210 (Pubitemid 30033708)
18. DJ Tenney SM Levine RE Rose AW Walsh SP Weinheimer L Discotto M Plym K Pokornowski CF Yu P Angus A Ayres A Bartholomeusz W Sievert G Thompson N Warner S Locarnini RJ Colonno 2004 Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 3498 3507 (Pubitemid 39129351)
19. P Colson P Borentain D Coso C Chabannon C Tamalet R Gerolami 2008 Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma Br J Haematol 143 148 150